Longeveron (LGVN) Competitors $1.87 +0.02 (+1.08%) (As of 11:20 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LGVN vs. DRRX, PLUR, LSTA, SCLX, COYA, VXRT, ANRO, MNPR, INMB, and IPSCShould you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include DURECT (DRRX), Pluri (PLUR), Lisata Therapeutics (LSTA), Scilex (SCLX), Coya Therapeutics (COYA), Vaxart (VXRT), Alto Neuroscience (ANRO), Monopar Therapeutics (MNPR), INmune Bio (INMB), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry. Longeveron vs. DURECT Pluri Lisata Therapeutics Scilex Coya Therapeutics Vaxart Alto Neuroscience Monopar Therapeutics INmune Bio Century Therapeutics DURECT (NASDAQ:DRRX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations. Which has better valuation & earnings, DRRX or LGVN? Longeveron has lower revenue, but higher earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDURECT$8.55M3.12-$27.62M-$0.61-1.41Longeveron$710K37.82-$21.41M-$6.28-0.30 Do institutionals and insiders hold more shares of DRRX or LGVN? 28.0% of DURECT shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 3.2% of DURECT shares are owned by company insiders. Comparatively, 19.1% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate DRRX or LGVN? DURECT presently has a consensus price target of $5.00, suggesting a potential upside of 481.33%. Longeveron has a consensus price target of $8.00, suggesting a potential upside of 327.81%. Given DURECT's higher possible upside, equities research analysts clearly believe DURECT is more favorable than Longeveron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DURECT 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Longeveron 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor DRRX or LGVN? In the previous week, DURECT had 11 more articles in the media than Longeveron. MarketBeat recorded 11 mentions for DURECT and 0 mentions for Longeveron. Longeveron's average media sentiment score of 0.75 beat DURECT's score of 0.25 indicating that Longeveron is being referred to more favorably in the news media. Company Overall Sentiment DURECT Neutral Longeveron Positive Is DRRX or LGVN more profitable? DURECT has a net margin of -198.58% compared to Longeveron's net margin of -967.49%. Longeveron's return on equity of -142.43% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets DURECT-198.58% -300.62% -65.17% Longeveron -967.49%-142.43%-100.84% Does the MarketBeat Community favor DRRX or LGVN? DURECT received 303 more outperform votes than Longeveron when rated by MarketBeat users. However, 92.86% of users gave Longeveron an outperform vote while only 63.84% of users gave DURECT an outperform vote. CompanyUnderperformOutperformDURECTOutperform Votes31663.84% Underperform Votes17936.16% LongeveronOutperform Votes1392.86% Underperform Votes17.14% Which has more risk and volatility, DRRX or LGVN? DURECT has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. SummaryDURECT and Longeveron tied by winning 9 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGVN vs. The Competition Export to ExcelMetricLongeveronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.85M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-0.304.9791.2813.60Price / Sales37.82371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book1.0510.306.906.33Net Income-$21.41M$153.61M$118.83M$225.93M7 Day Performance-10.10%-1.73%-1.92%-0.96%1 Month Performance-10.53%-7.26%-3.75%1.06%1 Year Performance-90.11%31.10%31.37%26.59% Longeveron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGVNLongeveron2.3938 of 5 stars$1.87+1.1%$8.00+327.8%-90.4%$26.85M$710,000.00-0.3023DRRXDURECT3.0843 of 5 stars$0.86-4.8%$5.00+481.3%+39.5%$26.70M$8.55M0.0080Analyst ForecastAnalyst RevisionNews CoverageGap DownPLURPluri0.1524 of 5 stars$4.96-2.0%N/A+11.5%$27.58M$330,000.00-0.82150LSTALisata Therapeutics3.3126 of 5 stars$2.92-0.3%$15.00+413.7%+33.6%$24.50MN/A-1.1730Analyst ForecastSCLXScilex3.4335 of 5 stars$0.56-0.9%$11.33+1,924.5%-48.7%$107.36M$46.74M0.0080Gap UpCOYACoya Therapeutics3.0472 of 5 stars$6.39+6.0%$16.67+160.8%+10.6%$106.78M$6M0.006VXRTVaxart2.1538 of 5 stars$0.60-1.2%$3.00+399.7%-22.1%$106.53M$7.38M-1.48109Analyst RevisionNews CoverageANROAlto Neuroscience3.8056 of 5 stars$3.88-9.1%$20.00+415.5%N/A$104.64M$210,000.000.00N/AAnalyst RevisionMNPRMonopar Therapeutics3.5896 of 5 stars$19.71+3.7%$27.33+38.7%+1,213.5%$104.07MN/A0.0010INMBINmune Bio2.1308 of 5 stars$4.68+2.6%$20.00+327.4%-39.1%$103.76M$160,000.00-2.0910IPSCCentury Therapeutics1.5761 of 5 stars$1.21-4.0%$11.60+858.7%-11.9%$102.89M$2.23M0.00170 Related Companies and Tools Related Companies DRRX Alternatives PLUR Alternatives LSTA Alternatives SCLX Alternatives COYA Alternatives VXRT Alternatives ANRO Alternatives MNPR Alternatives INMB Alternatives IPSC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LGVN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
